Urinary retention is the acute or chronic inability to voluntarily pass an adequate amount of urine. It is a urological emergency when acute, predominantly affects men, and is most commonly caused by benign prostatic hyperplasia (BPH), accounting for approximately 53% of cases. [1-2] Causes are classified as obstructive, infectious/inflammatory, pharmacologic, neurologic, or other. [2]
The following management algorithm illustrates the systematic approach to acute urinary retention:
1. History
- Onset and duration: Sudden (acute) vs. gradual (chronic); precipitating event (surgery, anesthesia, new medication)
- Voiding symptoms: Hesitancy, weak stream, intermittency, straining, sensation of incomplete emptying, dribbling
- Storage symptoms: Frequency, urgency, nocturia, incontinence (overflow)
- Pain: Suprapubic pain/fullness (present in acute, often absent in chronic retention)
- Fluid intake: Volume, caffeine, alcohol consumption [4]
- Medication review: Detailed inventory of prescription, OTC, and herbal supplements — this is critical [1]
- Surgical history: Recent surgery or anesthesia (postoperative retention is common)
- Neurologic symptoms: Back pain, leg weakness, saddle numbness, bowel dysfunction, sexual dysfunction
- Important negatives: Hematuria, fever/chills, dysuria, trauma, prior urethral instrumentation, history of STIs
2. Alarm Features
- Cauda equina syndrome: New bilateral sciatica, saddle anesthesia, bowel/bladder dysfunction, decreased rectal tone — requires emergent MRI [5-6]
- Spinal cord compression: Symmetric limb weakness, sensory level, urinary retention — emergent imaging and neurosurgical consultation [7]
- Urosepsis: Fever, tachycardia, hypotension in setting of urinary retention with infection
- Renal failure: Elevated creatinine, bilateral hydronephrosis (high-pressure chronic retention)
- Gross hematuria with clot retention: May indicate bladder or renal malignancy
- Failed catheterization: Inability to pass urethral catheter — urology consultation for suprapubic catheter [8]
3. Medications
Medications that cause urinary retention: [9-11]
- Anticholinergics/antimuscarinics: Oxybutynin, tolterodine, diphenhydramine, first-generation antihistamines, tricyclic antidepressants, antipsychotics (especially those with strong anticholinergic burden) [12]
- Opioids: Reduce detrusor contractility; commonly overlooked cause [13-14]
- Alpha-adrenergic agonists: Pseudoephedrine, phenylephrine (increase urethral sphincter tone)
- Benzodiazepines, calcium channel blockers, NSAIDs, gabapentin [9-10]
- Anesthetic agents: Spinal/epidural anesthesia (postoperative retention)
Treatments:
- Alpha-blockers (tamsulosin 0.4 mg daily, alfuzosin 10 mg daily): First-line pharmacotherapy; start at time of catheter insertion to improve trial without catheter (TWOC) success — 60% vs. 38% with placebo [15-16]
- 5-alpha reductase inhibitors (finasteride, dutasteride): For long-term BPH management; 3–6 months to effect [4]
- Avoid anticholinergics in patients with retention or significant PVR elevation
4. Diet
- Fluid management: Avoid excessive fluid intake; limit caffeine and alcohol, which exacerbate LUTS [4]
- Constipation prevention: High-fiber diet — constipation is a recognized precipitant and exacerbating factor for urinary retention [17]
- Alcohol: High consumption is an independent risk factor for acute urinary retention [18]
5. Review of Systems
- GU: Dysuria, hematuria, urethral discharge, penile/vaginal symptoms
- GI: Constipation, fecal incontinence, bowel habit changes (neurologic red flag)
- Neurologic: Back pain, radiculopathy, limb weakness/numbness, gait disturbance, saddle paresthesias
- Sexual: Erectile dysfunction, ejaculatory changes (may indicate neurologic or prostatic pathology)
- Constitutional: Fever, weight loss (malignancy, infection)
- Psychiatric: Depression, anxiety (associated with chronic pelvic pain/voiding dysfunction) [19]
6. Collateral History and Family History
- Collateral: Cognitive status in elderly patients (delirium can mask or precipitate retention); caregiver observations of voiding patterns [20]
- Family history: BPH, prostate cancer, neurologic diseases (multiple sclerosis, Parkinson disease)
- Social context: Mobility limitations, access to toileting, substance use (opioids, alcohol)
7. Risk Factors
- Age: Incidence rises sharply with age; mean age of ED presentation is 72 years; highest risk in 75–85 age group [16][21]
- BPH/LUTS: Pre-existing lower urinary tract symptoms are the strongest predictor [16]
- Race: African American and Hispanic men have higher rates of ED presentation for AUR, possibly reflecting undertreatment of BPH [21]
- Medications: Anticholinergics, opioids, sympathomimetics (see above)
- Comorbidities: Diabetes mellitus (autonomic neuropathy), neurologic disease (MS, stroke, spinal cord injury), constipation [17]
- Postoperative state: Anesthesia (especially spinal/epidural), immobility, opioid use
- Obesity, physical inactivity, high alcohol consumption [18]
8. Differential Diagnosis
- BPH (most common in men) [1]
- Prostatitis (acute bacterial — fever, tender prostate on DRE) [19]
- Urethral stricture (history of instrumentation, STI, trauma)
- Bladder neck obstruction
- Pelvic organ prolapse (most common obstructive cause in women) [2]
- Urinary tract infection/cystitis [2]
- Drug-induced retention [9]
- Neurogenic bladder (MS, spinal cord injury, diabetic neuropathy, stroke) [22]
Cannot-miss diagnoses:
- Cauda equina syndrome [5-6]
- Spinal cord compression (malignant or traumatic) [7]
- Bladder/prostate malignancy
- Urosepsis
- Clot retention from hematuria
9. Past Medical History
- Prior episodes of urinary retention or catheterization
- BPH, prostate cancer, prostate surgery (TURP)
- Urethral stricture disease, prior urethral instrumentation
- Neurologic conditions: MS, Parkinson disease, stroke, spinal cord injury, diabetic neuropathy
- Pelvic surgery or radiation
- Chronic constipation
- Diabetes mellitus
10. Physical Exam
- Vital signs: Fever (infection/sepsis), hypertension (pain, autonomic dysreflexia in SCI patients)
- Abdominal exam: Suprapubic distension, tenderness, palpable bladder
- Genital exam: Phimosis, meatal stenosis, urethral discharge, penile/scrotal pathology
- Digital rectal exam (DRE): Prostate size, tenderness (prostatitis), nodularity (cancer), rectal tone, fecal impaction — though digital prostate size correlates poorly with actual size [4]
- Pelvic exam (women): Pelvic organ prolapse, pelvic masses, vaginal atrophy
- Neurologic exam (critical): [1][14]
- Lower extremity strength, sensation, reflexes
- Saddle sensation (S2–S4 dermatomes)
- Anal tone and voluntary squeeze
- Bulbocavernosus reflex (absence suspicious for neurologic dysfunction, though 20% of healthy women lack it) [23]
- Gait assessment
11. Lab Studies
- Urinalysis: Rule out UTI, hematuria, glucosuria [4][22]
- Urine culture: If UTI suspected
- Basic metabolic panel/creatinine: Assess for renal insufficiency, especially in chronic retention or bilateral hydronephrosis [20]
- PSA: If prostate cancer is a concern (not indicated during acute prostatitis) [4][19]
- CBC: If infection or sepsis suspected
- Blood cultures: If febrile — 21% of patients with acute bacterial prostatitis have bacteremia [19]
- Gonorrhea/chlamydia testing: If STI risk factors present [19]
12. Imaging
- Bladder scan (point-of-care ultrasound): First-line for PVR measurement; preferred over catheterization for diagnosis [24]
- ≥300 mL in symptomatic patients → catheterize
- ≥500 mL in asymptomatic patients → catheterize [24]
- Renal ultrasound: Indicated if concern for hydronephrosis, chronic retention, or renal impairment [14]
- MRI spine: Emergent if cauda equina syndrome or spinal cord compression suspected [5][7]
- CT abdomen/pelvis: If concern for pelvic mass, stone, or malignancy
- Imaging is unnecessary for straightforward acute retention in a male with known BPH and no red flags
13. Special Tests
- Postvoid residual (PVR): Cornerstone of diagnosis; AUA defines chronic retention as PVR >300 mL on two occasions over ≥6 months [1]
- Uroflowmetry: Useful outpatient test for voiding dysfunction; only valuable in patients who can void [14]
- Urodynamics/video-urodynamics: Reserved for complex or neurogenic cases; assesses detrusor function, compliance, and outlet obstruction [14][25]
- Cystoscopy: If hematuria, suspected stricture, or bladder pathology
- International Prostate Symptom Score (IPSS): Validated questionnaire for LUTS severity (0–35 scale) [4]
14. ECG
- Not routinely indicated for urinary retention
- Consider ECG if:
- Autonomic dysreflexia in spinal cord injury patients (may cause hypertension, bradycardia)
- Pre-procedural assessment for surgical intervention
- Elderly patients with significant comorbidities presenting with hemodynamic instability
15. Assessment
Urinary retention is classified as acute (sudden, painful, complete inability to void) or chronic (gradual, often painless, with elevated PVR). [1-2] Acute retention is a urological emergency requiring immediate decompression. Causes are categorized as:
- Obstructive (BPH, stricture, prolapse, malignancy) — most common
- Infectious/inflammatory (prostatitis, UTI, urethritis)
- Pharmacologic (anticholinergics, opioids, sympathomimetics)
- Neurogenic (spinal cord lesion, cauda equina, MS, diabetic neuropathy)
- Postoperative (anesthesia-related, especially spinal/epidural)
Multiple mechanisms may coexist in a single patient, particularly in the elderly. [20] Mortality within the year following an AUR episode is higher than in the general population. [26]
16. Treatment Plan
Initial stabilization:
- Bladder catheterization with prompt and complete decompression — this is the immediate priority [1-2]
- Urethral catheterization is standard; suprapubic catheter if urethral catheterization fails or is contraindicated (urethral injury, artificial sphincter) [8][19]
- Intermittent catheterization preferred over indwelling for lower bladder volumes [24]
Pharmacotherapy:
- Start alpha-blocker at time of catheter insertion: Tamsulosin 0.4 mg daily or alfuzosin 10 mg daily [15-16]
- Trial without catheter (TWOC): Remove catheter after 48–72 hours of alpha-blocker therapy; success rate ~60% with alpha-blocker vs. ~38% with placebo [16][26]
- Prolonged catheterization >3 days does not improve TWOC success and increases complication risk [26-27]
- Discontinue offending medications when possible [9]
- Treat underlying infection if present (antibiotics for prostatitis/UTI) [19]
Definitive management (outpatient, urology-directed):
- BPH: Alpha-blockers ± 5-alpha reductase inhibitors for long-term management; surgical options (TURP, HoLEP, minimally invasive procedures) for refractory cases [4]
- Neurogenic bladder: Clean intermittent self-catheterization (CIC) is the mainstay [2][22]
- Urethral stricture: Dilation or urethroplasty
17. Disposition
Admission criteria: [20][26]
- Urosepsis or systemic infection
- Acute renal failure or significant electrolyte abnormalities
- Failed catheterization requiring urologic intervention
- Suspected cauda equina syndrome or spinal cord compression (emergent surgical consultation)
- Significant comorbidities requiring inpatient management (delirium, hemodynamic instability)
- Elderly patients with precipitating comorbid conditions (fecal impaction, delirium) [20]
Discharge criteria:
- Successful catheterization with adequate drainage
- Stable vital signs, no signs of infection or renal compromise
- Able to manage catheter at home (or with home health support)
- Alpha-blocker initiated, TWOC planned within 48–72 hours
- Reliable follow-up with urology or primary care
Urology consultation triggers: [8]
- Failed urethral catheterization
- Recurrent AUR
- Suspected urethral injury or stricture
- Patients with artificial urinary sphincters
- Need for long-term catheterization or surgical planning
18. Follow Up / Return Precautions
- TWOC scheduled within 2–3 days of catheter placement with alpha-blocker therapy [26-27]
- Urology follow-up within 1–2 weeks for all first-episode AUR; earlier if TWOC fails
- Return precautions: Inability to void after catheter removal, fever/chills, worsening suprapubic pain, hematuria, decreased urine output, signs of infection (cloudy/foul-smelling urine)
- Patient counseling: Avoid medications that worsen retention (OTC cold medications with pseudoephedrine, antihistamines); avoid excessive fluid intake or alcohol; manage constipation
- Expected course: With alpha-blocker therapy, ~60% of men with BPH-related AUR will void successfully after TWOC; those who fail typically require surgical intervention [15-16]
- Long-term monitoring: PVR measurement, renal function, and symptom assessment at follow-up visits [1]
References
1. Urinary Retention in Adults: Evaluation and Initial Management. — Serlin DC, Heidelbaugh JJ, Stoffel JT. American Family Physician. 2018.
2. Urinary Retention in Adults: Evaluation and Initial Management. — Serlin DC, Heidelbaugh JJ, Stoffel JT. American Family Physician. 2018.
3. Urinary Retention in Adults: Evaluation and Initial Management. — Serlin DC, Heidelbaugh JJ, Stoffel JT. American Family Physician. 2018.
4. Urinary Retention in Adults: Diagnosis and Initial Management. — Selius BA, Subedi R. American Family Physician. 2008.
5. Urinary Retention in Adults: Diagnosis and Initial Management. — Selius BA, Subedi R. American Family Physician. 2008.
6. Prostate Benign Prostatic Hyperplasia. — Daniel W. Good, Bashar Nahas, Simon Phipps, et al. Blandy's Urology, 3rd Edition. 2019.
7. Prostate Benign Prostatic Hyperplasia. — Daniel W. Good, Bashar Nahas, Simon Phipps, et al. Blandy's Urology, 3rd Edition. 2019.
8. Lower Urinary Tract Symptoms in Men. — Wei JT, Dauw CA, Brodsky CN. The Journal of the American Medical Association. 2025.
9. Lower Urinary Tract Symptoms in Men. — Wei JT, Dauw CA, Brodsky CN. The Journal of the American Medical Association. 2025.
10. Evaluation and Management of Cauda Equina Syndrome. — Kuris EO, McDonald CL, Palumbo MA, Daniels AH. The American Journal of Medicine. 2021.
11. Evaluation and Management of Cauda Equina Syndrome. — Kuris EO, McDonald CL, Palumbo MA, Daniels AH. The American Journal of Medicine. 2021.
12. Evaluation and Management of Cauda Equina Syndrome in the Emergency Department. — Long B, Koyfman A, Gottlieb M. The American Journal of Emergency Medicine. 2020.
13. Evaluation and Management of Cauda Equina Syndrome in the Emergency Department. — Long B, Koyfman A, Gottlieb M. The American Journal of Emergency Medicine. 2020.
14. Acute Spinal Cord Compression. — Ropper AE, Ropper AH. The New England Journal of Medicine. 2017.
15. Acute Spinal Cord Compression. — Ropper AE, Ropper AH. The New England Journal of Medicine. 2017.
16. Urinary Catheter Management. — Fletke KJ, Jeong DH, Herrera AV. American Family Physician. 2024.
17. Urinary Catheter Management. — Fletke KJ, Jeong DH, Herrera AV. American Family Physician. 2024.
18. Drug-Induced Urinary Retention: Incidence, Management and Prevention. — Verhamme KM, Sturkenboom MC, Stricker BH, Bosch R. Drug Safety. 2008.
19. Drug-Induced Urinary Retention: Incidence, Management and Prevention. — Verhamme KM, Sturkenboom MC, Stricker BH, Bosch R. Drug Safety. 2008.
20. Incontinence in frail elderly persons: Report of the 6th International Consultation on Incontinence. — Gibson W, Johnson T, Kirschner-Hermanns R, et al. Neurourology and Urodynamics. 2021.
21. Incontinence in frail elderly persons: Report of the 6th International Consultation on Incontinence. — Gibson W, Johnson T, Kirschner-Hermanns R, et al. Neurourology and Urodynamics. 2021.
22. Drug-Induced Bladder and Urinary Disorders. Incidence, Prevention and Management. — Drake MJ, Nixon PM, Crew JP. Drug Safety. 1998.
23. Drug-Induced Bladder and Urinary Disorders. Incidence, Prevention and Management. — Drake MJ, Nixon PM, Crew JP. Drug Safety. 1998.
24. Beers Criteria for Inappropriate Medication Use in Older Adults: Update From the American Geriatrics Society. — Arnold MJ. American Family Physician. 2024.
25. Beers Criteria for Inappropriate Medication Use in Older Adults: Update From the American Geriatrics Society. — Arnold MJ. American Family Physician. 2024.
26. Scan-Negative Cauda Equina Syndrome: A Prospective Cohort Study. — Hoeritzauer I, Carson A, Statham P, et al. Neurology. 2021.
27. Scan-Negative Cauda Equina Syndrome: A Prospective Cohort Study. — Hoeritzauer I, Carson A, Statham P, et al. Neurology. 2021.
28. Lower Urinary Tract Dysfunction in the Neurological Patient: Clinical Assessment and Management. — Panicker JN, Fowler CJ, Kessler TM. The Lancet. Neurology. 2015.
29. Lower Urinary Tract Dysfunction in the Neurological Patient: Clinical Assessment and Management. — Panicker JN, Fowler CJ, Kessler TM. The Lancet. Neurology. 2015.
30. Management of Urinary Retention in Patients With Benign Prostatic Obstruction: A Systematic Review and Meta-Analysis. — Karavitakis M, Kyriazis I, Omar MI, et al. European Urology. 2019.
31. Management of Urinary Retention in Patients With Benign Prostatic Obstruction: A Systematic Review and Meta-Analysis. — Karavitakis M, Kyriazis I, Omar MI, et al. European Urology. 2019.
32. The Role of Alpha Blockers Prior to Removal of Urethral Catheter for Acute Urinary Retention in Men. — Fisher E, Subramonian K, Omar MI. The Cochrane Database of Systematic Reviews. 2014.
33. The Role of Alpha Blockers Prior to Removal of Urethral Catheter for Acute Urinary Retention in Men. — Fisher E, Subramonian K, Omar MI. The Cochrane Database of Systematic Reviews. 2014.
34. Guidelines for preventing urinary retention and bladder damage during hospital care. — Johansson RM, Malmvall BE, Andersson-Gäre B, et al. Journal of Clinical Nursing. 2013.
35. Guidelines for preventing urinary retention and bladder damage during hospital care. — Johansson RM, Malmvall BE, Andersson-Gäre B, et al. Journal of Clinical Nursing. 2013.
36. Characteristics of recurrent acute urinary retention in BPH patients in the United States: Retrospective analysis of US‐based insurance claims database. — Lee S, Yoo KH, Kim TS, et al. The Prostate. 2023.
37. Characteristics of recurrent acute urinary retention in BPH patients in the United States: Retrospective analysis of US‐based insurance claims database. — Lee S, Yoo KH, Kim TS, et al. The Prostate. 2023.
38. Prostatitis. — Borgert BJ, Wallen EM, Pham MN. The Journal of the American Medical Association. 2025.
39. Prostatitis. — Borgert BJ, Wallen EM, Pham MN. The Journal of the American Medical Association. 2025.
40. Acute Urinary Retention in Elderly Men. — Thorne MB, Geraci SA. The American Journal of Medicine. 2009.
41. Acute Urinary Retention in Elderly Men. — Thorne MB, Geraci SA. The American Journal of Medicine. 2009.
42. Disparities in Benign Prostatic Hyperplasia Progression: Predictors of Presentation to the Emergency Department in Urinary Retention. — Patel PM, Sweigert SE, Nelson M, et al. The Journal of Urology. 2020.
43. Disparities in Benign Prostatic Hyperplasia Progression: Predictors of Presentation to the Emergency Department in Urinary Retention. — Patel PM, Sweigert SE, Nelson M, et al. The Journal of Urology. 2020.
44. The AUA/SUFU Guideline on Adult Neurogenic Lower Urinary Tract Dysfunction: Diagnosis and Evaluation. — Ginsberg DA, Boone TB, Cameron AP, et al. The Journal of Urology. 2021.
45. The AUA/SUFU Guideline on Adult Neurogenic Lower Urinary Tract Dysfunction: Diagnosis and Evaluation. — Ginsberg DA, Boone TB, Cameron AP, et al. The Journal of Urology. 2021.
46. Can We Improve Our Routine Urological Assessment to Exclude Neurogenic Causes for Lower Urinary Tract Dysfunction? ICI‐RS 2024. — Drake MJ, Arlandis S, Averbeck MA, et al. Neurourology and Urodynamics. 2025.
47. Can We Improve Our Routine Urological Assessment to Exclude Neurogenic Causes for Lower Urinary Tract Dysfunction? ICI‐RS 2024. — Drake MJ, Arlandis S, Averbeck MA, et al. Neurourology and Urodynamics. 2025.
48. Urinary Retention Evaluation and Catheterization Algorithm for Adult Inpatients. — Chrouser K, Fowler KE, Mann JD, et al. JAMA Network Open. 2024.
49. Urinary Retention Evaluation and Catheterization Algorithm for Adult Inpatients. — Chrouser K, Fowler KE, Mann JD, et al. JAMA Network Open. 2024.
50. Neurogenic lower urinary tract dysfunction: Clinical management recommendations of the Neurologic Incontinence committee of the fifth International Consultation on Incontinence 2013. — Drake MJ, Apostolidis A, Cocci A, et al. Neurourology and Urodynamics. 2016.
51. Neurogenic lower urinary tract dysfunction: Clinical management recommendations of the Neurologic Incontinence committee of the fifth International Consultation on Incontinence 2013. — Drake MJ, Apostolidis A, Cocci A, et al. Neurourology and Urodynamics. 2016.
52. The Reten-World Survey of the Management of Acute Urinary Retention: Preliminary Results. — Emberton M, Fitzpatrick JM. BJU International. 2008.
53. The Reten-World Survey of the Management of Acute Urinary Retention: Preliminary Results. — Emberton M, Fitzpatrick JM. BJU International. 2008.
54. Evaluation of the impact of a clinical pathway on the progression of acute urinary retention. — Gas J, Liaigre-Ramos A, Caubet-Kamar N, et al. Neurourology and Urodynamics. 2019.
55. Evaluation of the impact of a clinical pathway on the progression of acute urinary retention. — Gas J, Liaigre-Ramos A, Caubet-Kamar N, et al. Neurourology and Urodynamics. 2019.